Simulations Plus Debt to Equity Ratio 2010-2024 | SLP
Current and historical debt to equity ratio values for Simulations Plus (SLP) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Simulations Plus debt/equity for the three months ending August 31, 2024 was 0.00.
Simulations Plus Debt/Equity Ratio Historical Data |
Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
2024-08-31 |
$0.01B |
$0.18B |
0.08 |
2024-05-31 |
$0.01B |
$0.18B |
0.07 |
2024-02-29 |
$0.02B |
$0.18B |
0.10 |
2023-11-30 |
$0.01B |
$0.17B |
0.08 |
2023-08-31 |
$0.02B |
$0.17B |
0.10 |
2023-05-31 |
$0.01B |
$0.17B |
0.06 |
2023-02-28 |
$0.01B |
$0.17B |
0.05 |
2022-11-30 |
$0.01B |
$0.18B |
0.06 |
2022-08-31 |
$0.01B |
$0.18B |
0.06 |
2022-05-31 |
$0.01B |
$0.18B |
0.05 |
2022-02-28 |
$0.01B |
$0.17B |
0.07 |
2021-11-30 |
$0.01B |
$0.17B |
0.07 |
2021-08-31 |
$0.01B |
$0.17B |
0.09 |
2021-05-31 |
$0.01B |
$0.17B |
0.08 |
2021-02-28 |
$0.01B |
$0.16B |
0.09 |
2020-11-30 |
$0.01B |
$0.16B |
0.08 |
2020-08-31 |
$0.01B |
$0.16B |
0.08 |
2020-05-31 |
$0.02B |
$0.05B |
0.32 |
2020-02-29 |
$0.01B |
$0.04B |
0.20 |
2019-11-30 |
$0.01B |
$0.04B |
0.22 |
2019-08-31 |
$0.01B |
$0.04B |
0.20 |
2019-05-31 |
$0.01B |
$0.04B |
0.27 |
2019-02-28 |
$0.01B |
$0.03B |
0.29 |
2018-11-30 |
$0.01B |
$0.03B |
0.30 |
2018-08-31 |
$0.01B |
$0.03B |
0.36 |
2018-05-31 |
$0.01B |
$0.03B |
0.38 |
2018-02-28 |
$0.01B |
$0.03B |
0.40 |
2017-11-30 |
$0.01B |
$0.03B |
0.49 |
2017-08-31 |
$0.01B |
$0.03B |
0.49 |
2017-05-31 |
$0.00B |
$0.03B |
0.17 |
2017-02-28 |
$0.01B |
$0.02B |
0.21 |
2016-11-30 |
$0.01B |
$0.02B |
0.22 |
2016-08-31 |
$0.01B |
$0.02B |
0.22 |
2016-05-31 |
$0.01B |
$0.02B |
0.34 |
2016-02-29 |
$0.01B |
$0.02B |
0.37 |
2015-11-30 |
$0.01B |
$0.02B |
0.40 |
2015-08-31 |
$0.01B |
$0.02B |
0.40 |
2015-05-31 |
$0.01B |
$0.02B |
0.41 |
2015-02-28 |
$0.01B |
$0.02B |
0.45 |
2014-11-30 |
$0.01B |
$0.02B |
0.47 |
2014-08-31 |
$0.01B |
$0.02B |
0.36 |
2014-05-31 |
$0.01B |
$0.02B |
0.37 |
2014-02-28 |
$0.00B |
$0.01B |
0.16 |
2013-11-30 |
$0.00B |
$0.01B |
0.14 |
2013-08-31 |
$0.00B |
$0.01B |
0.13 |
2013-05-31 |
$0.00B |
$0.01B |
0.13 |
2013-02-28 |
$0.00B |
$0.01B |
0.12 |
2012-11-30 |
$0.00B |
$0.02B |
0.10 |
2012-08-31 |
$0.00B |
$0.02B |
0.15 |
2012-05-31 |
$0.00B |
$0.02B |
0.18 |
2012-02-29 |
$0.00B |
$0.02B |
0.22 |
2011-11-30 |
$0.00B |
$0.02B |
0.12 |
2011-08-31 |
$0.00B |
$0.01B |
0.13 |
2011-05-31 |
$0.00B |
$0.01B |
0.18 |
2011-02-28 |
$0.00B |
$0.01B |
0.17 |
2010-11-30 |
$0.00B |
$0.01B |
0.13 |
2010-08-31 |
$0.00B |
$0.01B |
0.12 |
2010-05-31 |
$0.00B |
$0.01B |
0.14 |
2010-02-28 |
$0.00B |
$0.01B |
0.19 |
2009-11-30 |
$0.00B |
$0.01B |
0.19 |
2009-08-31 |
$0.00B |
$0.01B |
0.16 |
2009-05-31 |
$0.00B |
$0.01B |
0.17 |
2009-02-28 |
$0.00B |
$0.01B |
0.21 |
Sector |
Industry |
Market Cap |
Revenue |
Computer and Technology |
Computer Software |
$0.580B |
$0.070B |
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
|